Drago Bratkovic

Dr. Drago Bratkovic

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
RLRiley Lisa
Riley Lisa
MNMichael Nafisinia
Michael Nafisinia
MMMinal J. Menezes
Minal J. Menezes
RNReta Nambiar
Reta Nambiar
AWAndrew Williams
Andrew Williams
JCJohn Christodoulou
John Christodoulou

7 November 2011 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
LRLaura Ivete Rudaks
Laura Ivete Rudaks
JNJillian K. Nicholl
Jillian K. Nicholl
DBDrago Bratkovic
Drago Bratkovic
CBChristopher P. Barnett
Christopher P. Barnett
Laura I. Rudaks, Jillian K. Nicholl, Drago Bratkovic, and Christopher P. Barnet

19 January 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
STSusan Thompson
Susan Thompson
AHAshley Hertzog
Ashley Hertzog
ASArthavan Selvanathan
Arthavan Selvanathan
KBKiera Batten
Kiera Batten
KLKatherine Lewis
Katherine Lewis
Kaustuv BhattacharyaKaustuv Bhattacharya
Kaustuv Bhattacharya
3-Hydroxy-3-Methylglutaryl-CoA Lyase (HMGCL) deficiency can be a very severe disorder that typically presents with acute metabolic decompensation with features of hypoketotic hypoglycemia, hyperammonemia, and metabolic acidosis. A retrospective chart and literature review of Australian patients over their lifespan, incorporating acute and long-term dietary management, was performed. Data from 10 patients contributed to this study. The index case of this disorder was lost to follow-up, but there is 100% survival in the remainder of the cases despite several having experienced life-threatening episodes. In the acute setting, five of nine patients have used 900 mg/kg/day of sodium D,L 3-hydroxybutyrate in combination with intravenous dextrose-containing fluids (delivering glucose above estimated basal utilization requirements). All patients have been on long-term protein restriction, and those diagnosed more recently have had additional fat restriction. Most patients take L-carnitine. Three children and none of the adults take nocturnal uncooked cornstarch. Of the cohort, there were two patients that presented atypically—one with fulminant liver failure and the other with isolated developmental delay. Dietary management in patients with HMGCL deficiency is well tolerated, and rapid institution of acute supportive metabolic treatment is imperative to optimizing survival and improve outcomes in this disorder.

19 September 2024 in Genetics in Medicine
Verified
Journal Article
Closed access
RRRocio Rius
Rocio Rius
ACAlison G Compton
Alison G Compton
NBNaomi L. Baker
Naomi L. Baker
SBshanti balasubramaniam
shanti balasubramaniam
SBStephanie Best
Stephanie Best
DTDavid R. Thorburn
David R. Thorburn


12 January 2026 in Genetics in Medicine
Verified
Journal Article
Open access
FSFrancjan J. Van Spronsen
Francjan J. Van Spronsen
HPHeidi Peters
Heidi Peters
LMLali Margvelashvili
Lali Margvelashvili
DADodo Agladze
Dodo Agladze
ISIda V.D. Schwartz
Ida V.D. Schwartz
AMAnia C. Muntau
Ania C. Muntau
To report interim results from the ongoing, open-label, phase 3 APHENITY Extension Study (NCT05166161), evaluating long-term treatment with sepiapterin in patients with phenylketonuria. Participants received an age-based dose of oral sepiapterin daily; those with mean blood phenylalanine (Phe) levels <360 μmol/L (<5.95 mg/dL) after 2 weeks underwent a 26-week dietary Phe tolerance assessment, wherein dietary Phe intake was adjusted and blood Phe levels monitored. Other participants continued treatment with optional diet liberalization. Primary endpoints included change from baseline to week 26 in dietary Phe intake and treatment-emergent adverse events (TEAEs). As of September 2, 2024, 169 participants received sepiapterin (median [minimum, maximum] age: 14.0 [0.2, 55.0] years, median exposure: 72.9 weeks); 102 participants underwent dietary Phe tolerance assessments. Mean (SD) dietary Phe intake increased from 27.6 (18.0) mg/kg/day at baseline to 62.5 (41.5) mg/kg/day at week 26 (least-squares mean change [SE]: 36.4 [2.8] mg/kg/day from baseline) (P < .0001 from post hoc analysis). The incidence of treatment-related TEAEs was 29.0%; 3 participants (1.8%) discontinued treatment owing to treatment-related TEAEs. There were no treatment-related serious TEAEs or deaths. Interim results support the long-term safety of sepiapterin and demonstrate the potential for diet liberalization in adults and children with phenylketonuria. NCT05166161 (https://www. gov/study/NCT05166161; date of registration, December 8, 2021).